Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
Johnson and Johnson
McKinsey
Merck

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEFTAZIDIME

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Ceftazidime

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00173901 ↗ Adverse Drug Reactions of Different Brands of Ceftazidime Injection Unknown status National Taiwan University Hospital Phase 4 2001-03-01 The purpose of this study is to understand whether generic ceftazidime causes different adverse drug reaction incidence from the brand drug.
NCT00210964 ↗ Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 2005-04-01 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00229008 ↗ Ceftobiprole in Hospital Acquired Pneumonia Completed Basilea Pharmaceutica Phase 3 2005-11-01 The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with nosocomial pneumonia.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Baxter Healthcare Corporation Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated GlaxoSmithKline Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Roche Pharma AG Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
NCT00333385 ↗ Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis Terminated Vaincre la Mucoviscidose Phase 4 2001-10-01 The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ceftazidime

Condition Name

Condition Name for Ceftazidime
Intervention Trials
Pneumonia 5
Cystic Fibrosis 5
Complicated Intra-abdominal Infection 4
Complicated Urinary Tract Infection 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ceftazidime
Intervention Trials
Infection 18
Infections 18
Communicable Diseases 16
Pneumonia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ceftazidime

Trials by Country

Trials by Country for Ceftazidime
Location Trials
United States 94
China 23
Japan 18
Spain 13
India 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ceftazidime
Location Trials
California 12
Ohio 9
Michigan 6
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ceftazidime

Clinical Trial Phase

Clinical Trial Phase for Ceftazidime
Clinical Trial Phase Trials
Phase 4 14
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ceftazidime
Clinical Trial Phase Trials
Completed 38
Unknown status 10
Recruiting 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ceftazidime

Sponsor Name

Sponsor Name for Ceftazidime
Sponsor Trials
Pfizer 24
AstraZeneca 17
Forest Laboratories 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ceftazidime
Sponsor Trials
Industry 69
Other 52
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Moodys
Medtronic
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.